MedImmune has inked a deal to pay Australia's Biota Holdings $5 million up front and up to $107.5 million in milestone payments for a collaboration to develop small-molecule compounds for preventing respiratory syncytial virus in infants. Gaithersburg-based MedImmune has developed Synagis for RSV. Article